Fundraising Fox
Exin Therapeutics
YC W25San Francisco, US · Founded 2024 · Delaware corporation · 9 employees · 7 known investors
Find your way into Exin Therapeutics
Sign up to see every warm intro you have to Exin Therapeutics
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Exin Therapeutics team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Exin Therapeutics develops an AI-guided drug discovery platform that uses experimental mouse studies to identify neurological therapies, starting with epilepsies linked to autism and Parkinson's disease. The company trains machine learning models on proprietary multimodal neuroscience data to guide its therapeutic screening process.
Also known as EI Therapeutics
Founders & leadership· Y Combinator alumni (W25)
Exin Therapeutics was founded in 2024 by Gabriel Ocana Santero, Marko Tvrdic, and Ivan Alex Priela Lazarte.
GO
Gabriel Ocana SanteroCEO and Co-founderGabriel Ocana Santero holds an MSc in Neuroscience and PhD in Pharmacology from Oxford University, with research experience spanning gene therapy, pancreatic cancer, and muscle physiology at institutions in Boston, Vienna, and Stockholm. He has conducted work on neurodevelopment and serotonin signaling at the Gatsby Unit at UCL, and now develops gene therapies for neurological conditions at Exin Therapeutics.
MT
Marko TvrdicCo-Founder & COOHe holds an MSc and PhD from Oxford and has research experience across molecular biology, neuroscience disciplines including retinal disorders, circadian biology, and neurodevelopment, with prior exposure to venture capital.
IA
Ivan Alex Priela LazarteCo-founder and Chief Scientific OfficerIvan Alex Priela Lazarte holds a DPhil in Physiology, Anatomy, and Genetics with research in brain development and function, combining molecular, systems-level, and computational biophysical approaches. He is an Executive Officer and Director at Exin Therapeutics, where he leads development of an AI-guided drug discovery platform for neurological therapies.
IL
Ivan LazarteFounderuntil 2026
Investors · 7
Alumni Ventureslisted by Alumni VenturesManchester · $100K – $10M
How we know: Y Combinator's founder network · av.vc · Not right? Tell us
Y Combinatorlisted by Y CombinatorSan Francisco · $500K
How we know: the Y Combinator directory · open dataset · 5k.vc investor directory · Not right? Tell us
468 CapitalreportedBerlin
How we know: the VCSheet dataset · Y Combinator's founder network · Not right? Tell us
Founder CapitalreportedSilicon Valley · $25K – $100K
How we know: Y Combinator's founder network · Not right? Tell us
OurCrowdreportedJerusalem
How we know: Y Combinator's founder network · Not right? Tell us
Tekedia CapitalreportedLagos · $1K
How we know: Y Combinator's founder network · Not right? Tell us
Theory VenturesreportedSan Francisco · $1M – $40M
How we know: Y Combinator's founder network · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$2.2M disclosed across 1 round · 2024
▶$2.2MraisedFeb 2026 · 28 investors · BiotechnologyRule 506(b)
▶$2.2MraisedFeb 2026 · 28 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Gabriel Ocana SanteroExecutive Officer, Director
- Ivan Alex Priela LazarteExecutive Officer, Director
- Marko TvrdicExecutive Officer, Director
- Offering amount
- $2.2M
- Amount sold
- $2.2M
- First sale
- Nov 2024
- Incorporated
- Corporation, Delaware, 2024
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Images
Related companies · 10
Mindstate Design LabsMindstate Design Labs is a clinical-stage drug development company that uses AI to map the biological basis of emotion and cognition, synthesizing psychedelic phenomenology and biochemical data to design pharmaceutical compounds that induce specific therapeutic emotional and cognitive states for mental health treatment.
Torpedo TherapeuticsTorpedo Therapeutics develops high-precision, closed-loop deep brain stimulation devices for treating neurological disorders including Parkinson's disease, essential tremor, dystonia, and drug-resistant epilepsy. The company uses micro- and nano-fabrication to create ultra-small electrode leads with machine learning-driven parameter adjustment to reduce side effects and improve treatment efficacy.
Enliven TherapeuticsEnliven Therapeutics is a clinical-stage biopharmaceutical company that discovers and develops small molecule therapeutics using a precision medicine approach, with a focus on oncology and hematology. Its discovery work combines clinically validated biological targets with differentiated chemistry to develop drugs for unmet medical needs.
NectomeNectome provides cryogenic preservation of the human body and brain shortly after legal death, aiming to preserve neural structure in sufficient detail that future revival may become theoretically possible. The service targets individuals at end-of-life seeking experimental preservation as a potential pathway to future recovery.
ClementiaIpsen is a biopharmaceutical group that publishes financial, legal, and non-financial reporting for shareholders, investors, and the public through documents such as its Universal Registration Document. The page is the investor reports and accounts section of the company's corporate site.
CircumventCircumvent develops precision medicines for neurodegenerative diseases, with current focus on Batten Disease and other rare neurological disorders. The company's research targets synaptic dysfunction and lysosomal pathways through investigation of the palmitoylome.
Well PrincipledWell Principled builds AI models for optimization across multiple domains: consumer durable purchasing behavior for marketing and supply chain planning, battery electrochemistry for materials science, and personalized metabolic modeling for fitness applications.
Iterion TherapeuticsIterion Therapeutics is a clinical-stage biopharmaceutical company developing cancer therapies targeting the Wnt/β-catenin pathway. Its lead candidate is in clinical trials for advanced hepatocellular carcinoma and other Wnt-driven tumors such as colorectal cancer.
SentynlA biopharmaceutical company developing novel medicines for rare diseases, serving patients and caregivers from early detection through therapeutic intervention.
BioworldBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
Companies working in the same space as Exin Therapeutics.
Legal entities · 1
corporate structureExin Therapeutics, Inc.
In the news
Frequently asked questions
- What does Exin Therapeutics do?
- Exin Therapeutics develops an AI-guided drug discovery platform that uses experimental mouse studies to identify neurological therapies, starting with epilepsies linked to autism and Parkinson's disease. The company trains machine learning models on proprietary multimodal neuroscience data to guide its therapeutic screening process.
- Who founded Exin Therapeutics?
- Exin Therapeutics was founded by Gabriel Ocana Santero, Marko Tvrdic, Ivan Alex Priela Lazarte in 2024.
- Who are Exin Therapeutics's investors?
- Exin Therapeutics's investors include Alumni Ventures, Y Combinator, 468 Capital, Founder Capital, OurCrowd, Tekedia Capital, Theory Ventures.
- How much funding has Exin Therapeutics raised?
- Exin Therapeutics has disclosed $2.2M raised across 1 round.
- Where is Exin Therapeutics headquartered?
- Exin Therapeutics is headquartered in San Francisco, US.